ESGCT 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
Cell & Gene Meeting on the Mesa 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.
The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 120+ dedicated presentations by the leading publicly traded and privately held companies in the space.
Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
UGent spin-off nominated for prestigious Nature Spinoff Prize
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
The Nature Spinoff Prize focuses on spin-offs that translate research in the life sciences or physical sciences into practical applications with added value for society. It offers academic entrepreneurs a unique opportunity to present their research to an international audience. The four finalists, including Trince, will present their innovative research live to a jury during the Curious2024 – Future Insight™ conference on July 10 in Mainz, Germany. The final winner will be announced on July 11.
Trince, founded in 2021 with support from UGent TechTransfer and the Industrial Research Fund (IOF), is committed to the development of photoporation. This innovative process was conceived by Professor Kevin Braeckmans, head of the biophotonics research group at Ghent University, and was awarded an EIC Grant from Horizon Europe earlier this year. At Trince, CSO Kevin Braeckmans, CEO Philip Mathuis and VP of Business Development Jan Van Hauwermeiren are supported by a Board of Directors, a Scientific Advisory Board and a dedicated team of researchers.
Trince stands for TRansfer INto CElls, and is engaged in the development and commercialization of a new technology within the biomedical/pharmaceutical sciences, better known as: photoporation. In this method of introducing external molecules into cells, the cells are first mixed with photothermal nanoparticles, which are then irradiated with laser light. The nanoparticles heat up locally due to the irradiation and create temporary pores in the membrane of the cells through which molecules can penetrate the cells. This approach minimizes internal cell damage, unlike current techniques such as electroporation.
Trince’s technology makes it possible, among other things, to genetically manipulate immune cells from the blood of cancer patients. These cells are modified to fight cancer cells after reintroduction into the patient’s body. The technology has the potential to save millions of lives in this way. Research into photoporation is currently focused on three key applications: the genetic modification of immune cells for cancer therapy, the genetic modification of stem cells, and live cell imaging.
ISSCR 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
The world’s best and brightest in stem cell research and regenerative medicine convene once a year for the ISSCR Annual Meeting, and you are invited! Join more than 4,000 scientists from around the globe at ISSCR 2024 to take part in a 4-day program comprising the year’s most significant new advances in the field.
BIO International Convention 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
Meet us at booth #4023
ISCT 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory, and Commercialization. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.
The word is out, Trince is longlisted for the Nature Spinoff Prize
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
We are working hard on our non-viral cell engineering platform and are happy to receive recognition for the potential and way forward of our technology. Thanks to the team we continuously improve and advance the possibilities of our platform, accommodating more cell types, bigger payloads, higher efficiencies, better functionalities, and viability. Onward to the next step: cGMP!
Special thanks to Universiteit Gent for the support thus far!
We are looking forward to the announcement of the finalists on June 25th.
European Innovation Council Awards
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
“We are grateful for the EIC’s support in funding the Penphomet project. It demonstrates that our breakthrough technology is addressing a crucial gap in the field of cell therapy,” said Philip Mathuis, CEO at Trince. “Together with our partners NecstGen and IBSAL, we are committed to advancing cell therapy manufacturing, ultimately benefiting patients and healthcare systems.”
Read more about the Penphomet Project with NecstGen, IBSAL and Trince.
Festival of Biologics Europe 2024
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
Over the years we have fostered strong relationships with local partners such as the Canton of Basel, Novartis, Roche and various incubators to cover the full pipeline of drug development. The congress features senior speakers from the top 50 pharmaceutical companies, biotechs, healthcare systems and academic groups creating endless networking opportunities.

